Two European studies came out this week, both with interesting implications. The first study came out of Denmark and noted that chronic lower back pain may be curable with an extended regimen of antibiotics.Â
Our second study may be even more important. In Germany, scientists studied 400 children and found that poor air quality is a contributor to Type 2 diabetes. It turns out that pollution creates a significant bump in insulin resistance, leading to diabetes.
Both of these studies will need larger trials to confirm the results. In this video, health-care analyst David Williamson discusses the potential impact for investors if both of these still-early results prove correct over time.Â
Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.
Copyright © 2009 The Motley Fool, LLC. All rights reserved.